About us

Uniogen—Enabling diagnosis and care at the first appointment. Our mission is to use advanced diagnostics to quickly identify pathogens and prevent their spread.

Uniogen is a global pioneer in clinical diagnostics, point-of-care testing, and instrumentation for life sciences. With our unique point-of-care tests, we provide patients and healthcare with faster, easier, and more cost-effective diagnostics of infectious diseases, cardiovascular diseases, and cancer—among others. Our mission is to enable diagnosis and care for patients at the first appointment.

GenomEra rapid PCR tests for SARS-CoV-2 / COVID-19 form a significant part of Uniogen’s current business. We also provide laboratory instruments and tests for the detection of anti-SARS-CoV-2 antibodies and other diseases through contract development and manufacturing services. Our Upcon® labeling system, coupled with state-of-the-art laboratory instruments and flexible software, brings high sensitivity and superior performance to point-of-care testing. 

“Uniogen’s three future pillars are: diagnostics of infectious diseases, diagnostics of cancers, and contract manufacturing.”

We are currently developing our first proprietary test, a unique glycovariant immunoassay, for the early detection of ovarian cancer. Ground-breaking for the market, we are also developing a complete solution for point-of-care testing with coupled immunoassay and PCR testing. This unique system will enable the diagnostics of several diseases simultaneously with a single, versatile, and easy-to-use device—virtually in any healthcare setting and with no special expertise.

Uniogen was established when Abacus Diagnostica, a frontrunner in molecular testing and rapid PCR tests, Kaivogen, a specialist in immunoassays and antibody testing, and Labrox, an innovator of high-end laboratory instruments and diagnostic readers, joined forces in 2022. The company is headquartered in Turku, Finland, and employs around 100 life science professionals. Uniogen’s products are sold in approximately 100 countries around the world. In 2021, the combined annual net sales of the three companies forming Uniogen were around 15 million euros.

“Together, we have limitless capacities for developing novel products and expanding our customer base. Uniogen’s new point-of-care testing solution under development will open great growth opportunities for us in the global diagnostics market.”

For more information on Uniogen’s services, please contact us here.